Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan/Paclitaxel vs Etoposide/Cisplatin in Extensive-Stage SCLC
NCT00006374Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 1999
- Primary completion
- Jun 2001
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of topotecan and paclitaxel in small cell lung cancer (SCLC) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Response Rate. Planned start Oct 1999; status: withdrawn.
02
Drugs
topotecanpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00006374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006374.